SECURITIES AND EXCHANGE COMMISSION

                           Washington, D.C. 20549-1004

                                    FORM 8-K
                    CURRENT REPORT PURSUANT TO SECTION 13 OF

                       THE SECURITIES EXCHANGE ACT OF 1934

       Date of Report (date of earliest event reported): June 1, 2004

                          MIRAVANT MEDICAL TECHNOLOGIES

             (Exact name of Registrant as specified in its charter)

   Delaware                               0-2554                 77-0222872
(State or other jurisdiction of     (Commission File Number)    I.R.S. Employer
incorporation or organization)                            Identification Number)





                                336 Bollay Drive
                             Santa Barbara, CA 93117

                    (Address of principal executive offices)

                                 (805) 685-9880

              (Registrant's telephone number, including area code)






ITEM 5.  Other Events

On  June  1,  2004,   the  Company   announced  that  the  U.S.  Food  and  Drug
Administration,  or  FDA,  has  accepted  for  filing  the  Company's  New  Drug
Application,  or  NDA,  for  SnET2  and  has  also  granted  a  Priority  Review
designation.   Acceptance   of  the  filing  means  that  the  FDA  has  made  a
determination  that the NDA meets the standard for substantive  review,  and the
Priority Review designation  expedites the review period. The Company is seeking
approval  from the FDA for its  proprietary  new drug SnET2 as a  treatment  for
patients with wet age-related macular  degeneration,  or AMD, a leading cause of
blindness in older adults.

Wet AMD is a major health problem with an estimated  500,000 new cases each year
worldwide. The disease is characterized by abnormal blood vessels at the back of
the eye that leak fluid and blood and can lead to severe loss of central vision.
The SnET2 treatment uses a light-activated  drug intended to selectively destroy
these abnormal blood vessels and stabilize vision loss.

A copy of the press release  issued on June 1, 2004 by Miravant  announcing  the
FDA  acceptance of our filing for review is attached  hereto as Exhibit 99.1 and
is incorporated by reference in its entirety.







ITEM 7.  FINANCIAL STATEMENTS ANDEXHIBITS

  Exhibit Number      Exhibit

     99.1 Press release dated June 1, 2004  announcing the acceptance for filing
          by the Food and Drug  Administration  of the  Company's  completed New
          Drug  Application  for SnET2 in the  treatment  of  patients  with wet
          age-related macular degeneration.








                SIGNATURE

     Pursuant to the  requirements  of the Securities  Exchange Act or 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                       Miravant Medical Technologies
                                      (Registrant)

Date:  June 2, 2004

                                            By:  /s/ John M. Philpott
                                            -------------------------
                                            Name:    John M. Philpott
                                            Title:   Chief Financial Officer







              Exhibit Index


Exhibit Number      Exhibit

     99.1 Press release dated June 1, 2004  announcing the acceptance for filing
          by the Food and Drug  Administration  of the  Company's  completed New
          Drug  Application  for SnET2 in the  treatment  of  patients  with wet
          age-related macular degeneration.